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Abstract: A new type of colon targeting system is presented, combining time-controlled and
enzyme-triggered approaches. Empty capsule shells were prepared by injection molding of blends of
a high-amylose starch and hydroxypropyl methylcellulose (HPMC) of different chain lengths. The
dissolution/erosion of the HPMC network assures a time-controlled drug release, i.e., drug release
starts upon sufficient shell swelling/dissolution/erosion. In addition, the presence of high-amylose
starch ensures enzyme-triggered drug release. Once the colon is reached, the local highly concentrated
bacterial enzymes effectively degrade this polysaccharide, resulting in accelerated drug release.
Importantly, the concentration of bacterial enzymes is much lower in the upper gastrointestinal tract,
thus enabling site-specific drug delivery. The proposed capsules were filled with acetaminophen
and exposed to several aqueous media, simulating the contents of the gastrointestinal tract using
different experimental setups. Importantly, drug release was pulsatile and occurred much faster in
the presence of fecal samples from patients. The respective lag times were reduced and the release
rates increased once the drug started to be released. It can be expected that variations in the device
design (e.g., polymer blend ratio, capsule shell geometry and thickness) allow for a large variety of
possible colon targeting release profiles.
Keywords: capsules; colon delivery; injection molding; swellable/soluble hydrophilic polymer;
bacteria-sensitive polymer
1. Introduction
In the field of oral modified-release, great efforts have been made since the 1990s to develop drug
delivery systems (DDSs) able to release the conveyed drug to specific regions of the gastrointestinal
tract [1–7]. In particular, the colon drew considerable attention as a target site for the treatment of
local disorders, such as inflammatory bowel diseases (e.g., ulcerative colitis and Crohn’s disease) and
irritable bowel syndrome, as well as for the prevention of colorectal adenocarcinoma [8–10]. Moreover,
the colonic region was investigated as a possible gateway to the systemic circulation, for instance to
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enhance the oral bioavailability of peptide and protein drugs [11–13]. Several strategies were proposed
to achieve colon-targeted systems, based on the exploitation of one or more of the physiological features
of the intestine [1].
Drug release into the large bowel was carried out using enzymatically degradable coatings,
triggered by the in situ activity of the microbiota [14,15]. Recent in vivo studies carried out in
healthy volunteers showed that these systems could be more reliable than pH-dependent ones [16,17].
The latter involve coatings dissolving above a pH value in the range of 5–7. Since the dissolution
of the coating takes some time (depending on its thickness and exact pH threshold value), these
systems should prevent the release of the incorporated drugs in the stomach and proximal bowel
and release the drug in the subsequent parts of the gastrointestinal tract. However, both premature
drug release in the small intestine, as well as no drug release at all, have been reported as potential
failures [18]. This can be attributed to the significant variability of the pH of the contents of the
different segments of the gastrointestinal tract. In this respect, attempts have been made to avoid
release failure, due to insufficient exposure of the enteric-soluble layer to fluid with appropriate pH, by
adding superdisintegrants to such coatings [19].
Polysaccharides such as chitosan, guar gum, pectin and chondroitin sulphate were used as
release-triggering components, to be specifically degraded by resident bacteria [20–22]. Starch
derivatives, especially those modified to resist pancreatic amylases, were also proposed [23–25].
However, the effectiveness of the above-mentioned materials as “colon carriers” is hampered by their
hydrophilicity/solubility, possibly leading to the failure of the barrier properties before the colon
is reached.
Time-dependent colonic DDSs were designed to undergo a silent phase of predetermined duration,
after which drug release takes place [26,27]. The lag phase is intended to correspond to the relatively
consistent small intestinal transit time, which is known to last about 3 h on average, with relatively
limited variability, despite differences in the size and density of the administered dosage forms and
feeding state of subjects [28]. In these cases, an external enteric film coating is needed to avoid variability
of drug release due to unpredictable gastric emptying. Over the years, a variety of time-dependent
reservoir systems have been described. Often, drug-containing cores are coated with layers based
on hydrophilic cellulose ethers, such as hydroxypropyl methylcellulose (HPMC), hydroxypropyl
cellulose (HPC), hydroxyethyl cellulose and calcium or sodium carboxymethylcellulose, in view of
their well-established safety, versatility and broad availability [29,30]. When exposed to aqueous
media, these polymers undergo more or less rapid swelling, dissolution and/or erosion, thus resulting
in a deferred onset of drug release. The duration of the lag phase can be programmed by selecting the
appropriate type of swellable/soluble hydrophilic polymer, its molecular weight (i.e., viscosity grade)
and the thickness of the applied layer. In the case of barriers based on HPMC, different chain lengths
and several coating techniques were studied [4,31]. More recently, time-dependent reservoir systems
in the form of capsules were proposed [32–34]. Particularly, HPC was the first thermoplastic cellulosic
derivative employed for the fabrication of capsule caps and bodies via injection molding (IM) to convey
drug-containing preparations [35,36]. The capsules registered under the name of Chronocap™ showed
the ability to release their contents after a predetermined lag phase, tunable according to the molecular
weight of the selected HPC and the thickness of the molded shell. Moreover, when used as the substrate
for enteric coating, the Chronocap™ system met the compendial gastroresistance requirements, while
maintaining the subsequent pulsatile release performance, thus proving suitable for time-dependent
colon delivery [37]. Because modulation of the lag phase could be a long and costly task, involving
the development of new formulations, molds and molding processes, the prototyping ability of 3D
printing by fused deposition modeling versus IM was recently investigated [38–40].
As a further development in the field of colon targeting, a novel path that combines microbiota
and pH-dependent approaches was described [41]. For this purpose, a pH-sensitive polymeric film
containing pancreatic amylase-resistant starch (added as enzyme-degradable pore former) was applied
to drug-loaded tablets. The obtained reservoir systems were studied in healthy volunteers to assess
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the site of disintegration using γ-scintigraphy. Disintegration of the dosage forms was consistently
observed at the ileocaecal junction or in the large intestine. Despite the increased chances of avoiding
failure in drug release, issues associated with a premature release were reported.
Given these premises, the aim of the study was to evaluate the suitability of IM for the
manufacturing of a novel type of capsules for colonic drug delivery, combining swellable/soluble
hydrophilic polymers and polysaccharides degraded by bacterial enzymes. The former component may
provide a lag phase due to a limited permeability and sufficient mechanical stability of the swollen gel in
the upper gastrointestinal tract, thus allowing the device to transit through the small intestine without
breaking up. On the other hand, the enzyme-degradable polymer, due to its selective degradation in
the colon, should speed up the in situ breakup of the capsule shell undergoing hydration/dissolution.
The combination of these two mechanisms, a “mixed time-controlled and enzyme-triggered approach”
for colon targeting, could in principle help circumventing inherent limitations and variability issues
related to single-trigger systems, thereby improving the site selectivity of drug release. Indeed, the
bacteria-sensitive component may enable prompt and complete release, even in the case of systems
with a lag phase that turns out longer than the real small intestine transit time, thus helping to prevent
drug release that is too late (and cases with no drug release at all).
2. Results and Discussion
2.1. Hot-Processability of the Starting Materials
Pharmaceutical-grade polymers were studied, which should, in principle, be suitable for the
development of reservoir systems allowing for colon delivery, relying on either the time-dependent or
the enzyme-triggered approach.
Among the possible swellable/soluble hydrophilic polymers currently used for the formulation
of pulsatile-release systems, HPC, HPMC and poly (vinyl alcohol) (PVA) were selected, based on
experience previously gained with respect to their hot-processability [42–44]. Due to the fact that
HPC, alone and in admixture with a plasticizer (i.e., polyethylene glycol 1500, PEG 1500), was studied
in terms of thermo-mechanical properties and melt-viscosity for the development of a dedicated
capsule-shaped mold, such a material was taken as a reference [36]. Moreover, a pilot industrial
plant for HPC extrusion provided with online control systems was developed and the compliance of
elemental and microbiological contaminants, as well as of by-products, with internal specifications
was assessed [40]. This would be of crucial importance in view of the need to demonstrate the safety
of the capsule under development. HPMC-based coating barriers applied by different techniques
onto drug-containing cores were already demonstrated, to be able to provide reproducible lag phases
prior to drug release [45]. Novel grades of HPMC with improved thermal properties (i.e., AffiniSol™)
were recently proposed and mainly employed for the preparation of solid dispersions [46–48]. These
grades are expected to maintain the crystallization-inhibiting properties of standard HPMCs, but can
be extruded over a wider range of temperatures than the latter. In order to allow for different release
profiles, AffiniSol™ with two different molecular weights was studied (i.e., HPMC 15LV and HPMC
4M). For the same reason, two PVA grades were selected (i.e., PVA 05 and PVA 40).
On the other hand, high amylose maize starch (i.e., Amylo® N-460, AMY) and modified
hydroxypropyl pea starch (i.e., Lycoat® RS780, LYC) were deemed interesting based on reports in the
literature concerning their enzymatic biodegradability [49,50]. In addition, starch itself and a few of its
derivatives were successfully processed by hot melt extrusion (HME) and IM [51,52]. In these cases,
mixtures of water and glycerol (GLY) were used as plasticizers.
Based on prior art knowledge, a preliminary HME study was performed, comparing different
formulations (i.e., varying in the type and amount of plasticizer) and processing parameters. Suitable
conditions were identified by progressively adjusting the temperature and screw speed, recording the
extrusion stress and qualitatively evaluating the obtained products (e.g., transparency, homogeneity,
presence of signs highlighting breaking of the flow, resistance to manual breaking) (Table 1).
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Table 1. Composition, processing parameters and pictures of extrudates based on different polymers.
HPC HPMC15LV HPMC 4M PVA 05 PVA 40 AMY LYC
Plasticizer
(% w/w)
PEG 1500
(10)
PEG 1500
(10)
PEG 1500
(10) GLY (15) GLY (15)
GLY (20) +
water (15)
GLY (10) +
water (5)
Temperature
(◦C) 150 155 160 170 190 105 100
Screw
Speed (rpm) 50 80 80 50 30 75 50
Torque
(N·cm) 25 60 80 40 95 60 80
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Like the reference HPC, both investigated grades of HPMC could be processed at a temperature 
≤ 160 °C when adding 10% PEG 1500. Despite the good characteristics of the PVA-based extrudates 
in terms of homogeneity, transparency and resistance to manual breaking, both grades of this 
polymer required relatively high processing temperatures, independent of the amount of added 
plasticizer (GLY). According to the literature, HME of starch derivatives generally requires the 
addition of a mixture of plasticizers, often water and GLY. The latter promote the formation of 
thermoplastic starch under heat and shear stresses [53,54]. Such a phenomenon, i.e., gelatinization, 
refers to the disruption of the granule structure of the starch, with loss of order and crystallinity, 
following the reduction of the hydrogen bonds between molecules with ease of mutual movements. 
Some of the main disadvantages associated with thermoplastic starch include retrogradation 
and unsatisfactory mechanical properties (i.e., fragility). Importantly, the presence o GLY can 
help in avoiding these drawbacks, and GLY does not easily evaporate during processing. When 
AMY was extruded, higher amounts of plasticizers and higher screw speed were required 
compared to LYC to obtain extrudates with similar, desired characteristics. 
The first IM trials were used to manufacture polymeric disks. The process involves the flowing 
of a melt in all directions from a central injection point to the equidistant walls of the mold. These 
disk-shaped devices were shown to be very useful for the evaluation of the processability of 
polymeric formulations by IM [33]. In particular, the diameter of the disks with respect to that of the 
mold, and the need for intervention during the ejection process, as a consequence of the adhesion of 
the object to the mold, were the parameters used to define a “qualitative processability scale” 
describing a single batch, i.e., the molding of 30 consecutive items. Moreover, the disks could be used 
to investigate the mechanism of interaction with aqueous fluids (i.e., water uptake and 
dissolution/erosion rate) of the polymeric formulations and, using them to close the donor 
compartment of modified permeability cells, the relevant release-controlling potential could be 
studied in a quantitative manner, i.e., measuring the time needed to rupture the sample. In view of 
the final goal, i.e., the development of a delivery platform combining time-dependent and 
microbiological approaches for colon targeting, not only formulations based on single polymers (i.e., 
either swellable/soluble hydrophilic polymers or starch derivatives), but also combinations (1:1 
weight: weight ratio) of two polymeric formulations, composed of a swellable/soluble hydrophilic 
polymer and of a bacterial degradation-sensitive polymer, respectively, were taken into account. 
Preliminary studies relevant to disk manufacturing allowed the setup of adequate process 
parameters, i.e., temperature and injection pressure, time as well as rate. These are reported in Table 
2 together with processability scores for each polymeric formulation employed and pictures of the 
best products that were obtained.
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Like the reference HPC, both investigated grades of HPMC could be processed at a temperature ≤
160 ◦C when adding 10% PEG 1500. Despite the good characteristics of the PVA-based extrudates in
terms of homogeneity, transparency and resistance to manual breaking, both grades of this polymer
required relatively high processing temperatures, independent of the amount of added plasticizer
(GLY). According to the literature, HME of starch derivatives generally requires the addition of a
mixture of plasticizers, often water and GLY. The latter promote the formation of thermoplastic
starch under heat and shear stresses [53,54]. Such a phenomenon, i.e., gelatinization, refers to the
disruption of the granule structure of the starch, with loss of order and crystallinity, following the
reduction of the hydrogen bonds between molecules with ease of mutual movements. Some of the
main disadvantages associated with thermoplastic starch include retrogradation and unsatisfactory
mechanical properties (i.e., fragility). Importantly, the presence of GLY can help in avoiding these
drawbacks, and GLY does not easily evaporate during processing. When AMY was extruded, higher
amounts of plasticizers and higher screw speed were required compared to LYC to obtain extrudates
with similar, desired characteristics.
The first IM trials were used to manufacture polymeric disks. The process involves the flowing
of a melt in all directions from a central injection point to the equidistant walls of the mold. These
disk-shaped devices were shown to be very useful for the evaluation of the processability of polymeric
formulations by IM [33]. In particular, the diameter of the disks with respect to that of the mold, and
the need for intervention during the ejection process, as a consequence of the adhesion of the object to
the mold, were the parameters used to define a “qualitative processability scale” describing a single
batch, i.e., the molding of 30 consecutive items. Moreover, the disks could be used to investigate the
mechanism of interaction with aqueous fluids (i.e., water uptake and dissolution/erosion rate) of the
polymeric formulations and, using them to close the donor compartm nt of modifi d permeability cells,
the re ev t rel as -cont olling po e tial could b studied in a qu ntitative man r, i.e., measur ng the
time need d t rupture the sample. In view of the final g al, i.e., the deve opment of a deliver platform
combin ng time-dependent and micr biological approaches for colon targeting, not only formulations
based on ingle polymers (i.e., either swell ble/soluble hydrophilic polymers or starch derivatives),
but also combinations (1:1 weight: weight ratio) of two polymeric formulations, composed of a
swellable/soluble hydrophilic polymer and of a bacterial degradation-sensitive polymer, respectively,
were taken into account. Preliminary studies relevant to disk manufacturing allowed the setup of
adequate process parameters, i.e., te perature and injection pressure, time as well as rate. These are
reported in Table 2 together with processability scores for each polymeric formulation employed and
pictures of the best products that were obtained.
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Table 2. Process parameters and pictures (the side of the squares in the background is 0.5 mm long) of molded disks, based on different polymeric formulations.
Plasticized Formulation
Based on
Process Parameters
Processability *Temperature (◦C) Injection Pressures,
P1–P2 (bar)
Injection Times,
t1–t2 (s)
Injection Rates,
v1–v2 (%)Compression
Zone
Metering
Zone Nozzle
AMY
Powder 110 115 130 70-60 0.8-0.3 40-20 -/+
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AMY 
Powder 110 115 130 70-60 0.8-0.3 40-20 -/+
Extruded pellets 110 120 140 70-60 0.8-0.3 40-20 -/+ 
LYC 100 125 135 70-60 0.8-0.3 50-30 -
HPC 145 150 165 50-40 0.8-0.3 50-40 ++
HPMC 15LV 155 165 175 50-30 0.8-0.3 30-10 ++
HPMC 4M 175 180 185 60-50 1.5-1.0 60-50 ++
PVA 05 155 165 170 50-30 0.8-0.3 50-30 +
PVA 40 170 175 180 70-50 0.8-0.3 70-50 +/-
AMY/HPC 125 125 135 60-50 0.8-0.3 30-20 +
AMY/HPMC 15LV 125 125 135 30-20 2.0-1.5 30-10 +
AMY/HPMC 4M 135 135 155 60-50 0.8-0.3 60-40 +
Extruded pellets 110 120 140 70-60 0.8-0.3 40-20 -
LYC 100 125 135 70-60 0.8-0.3 50-30 -
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Extruded pellets 110 120 140 70-60 0.8-0.3 40-20 -/+ 
LYC 100 125 135 70-60 0.8-0.3 50-30
HPC 145 150 165 50-40 0.8-0.3 50-40 ++
HPMC 15LV 155 165 175 50-30 0.8-0.3 30-10 ++
HPMC 4M 175 180 185 60-50 1.5-1.0 60-50 ++
PVA 05 155 165 170 50-30 0.8-0.3 50-30 +
PVA 40 170 175 180 70-50 0.8-0.3 70-50 +/-
AMY/HPC 125 125 135 60-50 0.8-0.3 30-20 +
AMY/HPMC 15LV 125 125 135 30-20 2.0-1.5 30-10 +
AMY/HPMC 4M 135 135 155 60-50 0.8-0.3 60-40 +
HPC 145 150 165 50-40 0.8-0.3 50-40 ++
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AMY/HPMC 15LV 125 125 135 30-20 2.0-1.5 30-10 +
AMY/HPMC 4M 135 135 155 60-50 0.8-0.3 60-40 +
HPMC 15LV 155 165 175 50-30 0.8-0.3 30-10 ++
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AMY/HPMC 15LV 125 125 135 30-20 2.0-1.5 30-10 +
AMY/HPMC 4M 135 135 155 60-50 0.8-0.3 60-40 +
HPMC 4M 175 180 185 60-50 1.5-1.0 60-50 ++
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Table 2. Cont.
Plasticized Formulation
Based on
Process Parameters
Processability *Temperature (◦C) Injection Pressures,
P1–P2 (bar)
Injection Times,
t1–t2 (s)
Injection Rates,
v1–v2 (%)Compression
Zone
Metering
Zone Nozzle
AMY/HPMC 4M 135 135 155 60-50 0.8-0.3 60-40 +
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Since the injection cycle was shorter than the HME process and the temperature could be
progressively increased along the different sections of the press, it was possible to set higher temperatures
for IM than for HME, especially in the case of the investigated starch derivatives, without impacting
the product quality. In particular, temperatures in the metering zone and in the nozzle were increased
in order to achieve a viscosity of the melt, enabling the complete filling of the mold cavity. AMY
was used to evaluate whether an optional HME of the polymeric formulation prior to IM affected
the thermoplastic behavior of the starch derivatives. The plasticized AMY formulation was directly
introduced into the micromolding equipment. Alternatively, the equipment was fed with extruded
pellets, prepared with the same plasticized AMY formulation. The water content of the extruded
pellets turned out to be critical for the subsequent IM process. In fact, optimal operating IM parameters
set for the polymeric formulation and the pellets were the same, except for the temperature, which
needed to be slightly increased for the pellets. This could be attributed to the lower water content of
the pellets, some of the water probably being lost during the HME process. Irrespective of an optional
HME step, AMY showed a good moldability, even if disks needed to be manually removed from
the ejector. In contrast, the processability of the LYC formulation was not satisfying, with recurrent
blockage of the apparatus and sporadic achievements of entire and non-deformed disks. This behavior
was not altered when adding HME step and feeding the micromolding equipment with the obtained
pellets. Among the investigated formulations based on swellable/soluble hydrophilic polymers, only
PVA (especially the higher molecular weight grade PVA 40), showed poor processability, even when
increasing the temperatures and the amounts of plasticizer.
The plasticization conditions found suitable for molding the formulations based on single polymers
turned out to be also appropriate for the respective blends. Moreover, the processing temperatures
and the final characteristics of the obtained products were found to be similar for formulations based
on the respective single polymers and blends. In particular, processing was especially challenging in
the case of blends, including at least one polymeric formulation, which showed difficulties during
molding as single polymer formulation. Specifically, no disks were obtained that could be tested in the
modified permeability cells that were based on single polymer formulations or blends containing LYC
and PVA 40.
2.2. Performance of Molded Disks
2.2.1. Interaction with Aqueous Fluids
In order to assess the potential of the selected formulations to act as release-controlling barriers,
molded disks were preliminarily tested for interaction with aqueous fluids.
The dynamic changes in the water content (WC) and residual dry mass (RDM) of disks based on
AMY or LYC, optionally blended with different swellable/soluble hydrophilic polymers upon exposure
to phosphate buffer pH 6.8, are shown over 8 h in Figure 1; Figure 2, respectively. For reasons of
comparison, the behavior of the respective disks based on the swellable/soluble hydrophilic polymers
are also shown.
AMY-based disks showed a moderate uptake of water during the first minutes of testing, without
any evidence for major increase in volume. The water content reached was about constant over time.
Accordingly, after an initial moderate dry mass loss, no further reduction was observed. The RDM
value remained relatively high (≥ 80%) until the end of the experiment. This is likely due to the high
amount of amylose, providing resistance to dissolution/erosion. However, after a few hours of testing,
a tendency of AMY-based disks to exfoliation was noticed (Figure 3). This phenomenon also affected
the barrier performance, leading to the rupture of the disks in less than 30 min (the earlier rupture
in this case can probably be attributed to the more stressful hydrodynamic conditions encountered
during this type of experiment). Disks based on AMY, but prepared via an additional HME step,
behaved similarly with respect to their water uptake, mass loss and exfoliation behavior. On this basis,
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the extrusion step was considered not to be essential for the subsequent IM process. Therefore, the
direct molding of powders was carried out during all further experiments.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 8 of 22 
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Figure 1. Dynamic changes in WC and RDM of disks based on AMY or blends of AMY with a
swellable/soluble polymer hydrophilic upon exposure to phosphate buffer pH 6.8. For reasons of
comparison, the behavior of disks based on the respective swellable/soluble hydrophilic polymer
are also shown. * in the WC profiles marks the last recorded data before the complete dissolution
of samples.
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AMY-based disks showed a moderate uptake of water during the first minutes of testing, 
without any evidence for major increase in volume. The water content reached was about constant 
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The RDM value remained relatively high (≥ 80%) until the end of the experiment. This is likely due 
Figure 2. Dynamic changes in WC and RDM of disks based on LYC or blends of LYC with a swellable/
soluble hydrophilic polymer upon exposure to phosphate buffer pH 6.8. For reasons of comparison,
the behavior of disks based on the respective swellable/soluble hydrophilic polymer are also shown.
* in the WC profiles marks the last recorded data before the complete dissolution of samples.
Disks based on HPC, PVAs and HPMCs showed generally higher water uptake rates and extents
and more pronounced and more rapid dry mass loss kinetics upon exposure to phosphate buffer pH 6.8
than disks based on AMY (Figure 1; Figure 2). As expected, the swelling ability and dissolution/erosion
rate were related to the type and molecular weight of the polymer. HPMC 4M- and PVA 40-based
Int. J. Mol. Sci. 2020, 21, 1917 10 of 21
samples, in particular, achieved a water content above 85% and maintained it over 8 h, accompanied
by a significant mass loss. However, they did not completely dissolve in the observation period (8 h),
maintaining RDM values of approximately 30% and 50% for PVA 40- and HPMC 4M-based items,
respectively. The dissolution/erosion process of disks based on HPC and on the lower molecular
weight grades of both PVA and HPMC was relatively fast and complete in about 2 h. These results
were consistent with the observed rupture times of the disks tested using the modified permeability
cells (i.e., HPMC 4M >> HMPC 15LV > PVA 05 ≈ HPC).
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Figure 3. Picture of an AMY-based disk after 5h exposure to phosphate buffer pH 6.8.
According to the combination of approaches to provide colon delivery as pursued in this study, the
dissolution/erosion of the gel barrier is intended to be sufficiently slow to ass re that th devic s may
pass intact through the small int stine and provide an appropriate lag time p ior to drug rel ase. This is
why it was import nt to also investigate the behavio of disks based on the respective polymer blends.
In the case of disks b sed ither on HPC or PVA 05, the addition of AMY strongly reduced the time
needed for complete dissolution, by 50% or ev n 75%. While a slight decr ase in the w ter content was
observed with discs containi g HPMC of both molecular weights whe adding AMY, no major impact
n the respective ry mass loss was found. Th s, this type of polymer ble might be particul rly
promising in view of the desired behavior. No AMY/PVA 40-based disks could be withdrawn at the
end f the test, even though the initial mass loss rate was simil r to that of disks based on PVA 40 only.
This might b attributable to the lack of integrity and low quality of the disks even befor exposure to
the phosphate buffer, which also made their testing in the barrier performance experiments impossible.
The ruptu e times observed during the latter tests with the other types of disks confirmed the above
described observatio wit respect to the water uptake and mass lo s kinetic (i.e., AMY a dition
led to increased rupture times in the case of HPMC 15LV- and HPMC 4M-containing prototyp s nd
decreased rupture times in the c se of HPC- and PVA 05-containing disks). Interestingly, the xf liation
issues observed with disks based on AMY only we e not encountered in any of the relevant blends.
Disks bas on LYC showed a slower water uptak compared to AMY-based disks, but a complete
mass loss in les than 3 h, which was expected considering the soluble nature of this polymer. When
used in blends, LYC se m d not to acceler te the mas l ss of disks with res ct to prototypes based on
the corresponding swellable/soluble hydrophilic polymer only, especially in the case of HPC, PVA 05
and HPMC 15LV. However, a consid rable variability w s observed with all LYC-containing sample ,
probably due to the above-mentioned poor qu lity of t molded it ms. Indeed, no entire disks for the
m asur ments of rupture times were obtained. For t ese reasons, LYC was di carded from furth
experi e ts. On the other hand, blends of AMY with both grades of HPMC seemed to be the most
promising can idates at this stag nd wer further investigated.
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2.2.2. Interactions with Culture Medium +/- Fecal Samples
According to the combined approach proposed here for colon delivery, the presence of the
bacteria-sensitive component is intended to promote the fast opening of capsules once the site of
interest is reached, due to specific degradation by enzymes secreted by the local microbiota. The use of
biorelevant media, e.g., based on rat cecal contents and human fecal slurries, was already demonstrated
to be a suitable strategy to evaluate the role of polysaccharide fermentation as a trigger for drug
release [55]. Relying on the data described above obtained with phosphate buffer, disks based on
AMY/HPMC 15LV and AMY/HPMC 4M were selected for further testing in aqueous fluids containing
fecal bacteria. For reasons of comparison, disks based on AMY only were also studied. Please note
that in addition to the 600 µm thick “standard” disks, 200 µm thick disks were also prepared by IM
and studied. Figure 4 shows the dynamic changes in the WC and RDM of disks based on AMY,
AMY/HPMC 15LV and AMY/HPMC 4M (200 or 600 µm thickness) upon exposure to culture medium
free of fecal samples or inoculated with fecal samples, under anaerobic conditions.
As can be seen, disks based only on AMY confirmed their ability to take up and maintain a roughly
constant water content during at least two days, irrespective of their thickness and the presence/absence
of fecal samples. All the prototypes tested in the culture medium free of feces showed a mass loss
of approximately 20% in the first 24 h, with no further changes in the rest of the experiment. This
could be explained by the exfoliation behavior already observed in phosphate buffer for the same
type of disks. However, when they were in contact with the fluids enriched with feces, a reduction in
RDM values was observed, which was more evident with the thinnest barriers (i.e., mass loss about
50%). Such results indicate that colonic bacteria effectively cause the fermentation of the investigated
starch derivative upon molding. The addition of swellable/soluble HPMC led to increased WC and
accelerated mass loss, as expected (Figure 4b,c versus 4a). This is due to the hydrophilic nature and
water solubility of the HPMC. Please note that in the case of the shorter chain HPMC, earlier sampling
time points were used (i.e., 15 and 20 h). The presence/absence of fecal samples only slightly affected
the measured dry mass loss behavior of the investigated 600 µm thick disks based on AMY/HPMC
4M under the given conditions. However, thinner disks (200 µm) showed a much more pronounced
mass loss in the presence of fecal bacteria (Figure 4b). This is likely due to the fact that enzymatic
degradation becomes more easily visible in the case of thinner samples (with a lower staring mass).
However, in the case of injection molded AMY/HPMC 15LV disks that were 600 µm thick, a clear
impact of the presence of fecal bacteria on the mass loss kinetics was visible (Figure 4c), indicating
the sensitivity of these systems towards bacterial enzymes. The difference between HPMC 4M and
HPMC 15LV containing samples can again be attributed to the different chain lengths of these polymers
(please see above). In brief, HPMC 15LV leads to faster dissolution/erosion, thus favoring the attack of
bacterial enzymes.
2.3. Manufacturing of and Drug Release from Capsules
In view of the promising results in terms of sensitivity to the colonic bacteria degradation observed
with AMY in admixture with HPMC of different molecular weight, empty capsule shells with a
nominal wall thickness of 600 µm based on these polymer blends were prepared by IM. Table 3 shows
the final processing conditions and pictures of the respective capsules. For reasons of comparison,
capsule caps and bodies based on single plasticized polymers are also shown. Please note that
the processing conditions are slightly different from those applied for the manufacturing of the
corresponding disks, because of the differences in the mold geometry and dimensions (e.g., halved
thickness in the overlapping area between the cap and the body). For instance, the temperatures had
to be increased in the hot runner to ensure a proper flow of the melt and allow its progression into the
cavity. Overall, the IM process turned out to be slightly more challenging compared to the fabrication
of the above described disks. Nevertheless, it was possible to obtain capsule shells with the desired
physico-technological characteristics (i.e., reproducible weight and thickness, body and cap details
enabling appropriate matching and leading to a seal closure of the capsules).
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Table 3. Process parameters and pictures of molded empty capsule caps and bodies based on different polymers.
Formulation
Process Parameters
Processability *Temperature (◦C) Injection Pressures,
P1–P2 (bar)
Injection Times,
t1–t2 (s)
Injection Rates,
v1–v2 (%)Compression
Zone
Metering
Zone Nozzle
Hot
Runner
AMY 110 115 130 135 70–60 0.8–0.3 40–20 +/−
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Filled and assembled capsules were tested in a basket-rack assembly of a modified disintegration
apparatus (as reported in 3.2.6). The latter had been demonstrated to be adequate for the evaluation of
reservoir systems based on swellable/soluble hydrophilic polymers, allowing the improvement of the
reproducibility of release measurements and avoiding sticking, as well as floating issues [35,36].
Figure 5 illustrates the observed release kinetics of acetaminophen from capsules based on
AMY/HPMV 15LV or AMY/HPMC 4M blends. For reasons of comparison, drug release from capsules
based on HPMC 4M or HPMC 15LV is also shown. Note that the investigated capsules based on AMY
only showed poor mechanical resistance under the given conditions (Figure 6), resulting in immediate
release (data not shown). This was attributed to the above-described exfoliation behavior. The release
performance was consistent with that of starch-based molded capsules registered under the trade
name Capill® [56–58]. On the other hand, HPMC-based capsules exhibited a pulsatile release profile,
characterized by lag phases of different duration prior to release (Figure 5). These differences may be
attributed to the characteristics of the swollen system (e.g., gel strength). The slower erosion/dissolution
of the gel barrier based on HPMC 4M compared to HPMC 15LV was also reflected in a different time
for complete release (i.e., 3 times longer than that of HPMC 15LV-based capsules). The addition of
AMY to HPMC 15LV based capsules did not substantially alter the overall pulsatile release kinetics of
these systems, which is consistent with the dry mass loss kinetics of the respective disks (please see
above). Importantly, the addition of AMY significantly prolonged the lag time observed with HPMC
4M-based capsules (Figure 5). This illustrates the ability of AMY to slow down the hydration and
dissolution/erosion of the HPMC gel.
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Figure 6. Pictures of capsules based on AMY only after 30 min exposure to phosphate buffer pH 6.8 in
a modified disintegration apparatus.
To evaluate the possible role of AMY in the capsule shell as an enzyme-trigger, AMY/HPMC
15LV and AMY/HPMC 4M capsules were filled with acetaminophen and exposed to culture medium
free of fecal samples, and culture mediu inoculated with fecal samples from patients suffering from
inflammatory bowel diseases (Figure 7).
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upon exposure to culture medium free of bacteria, and culture medium inoculated with fecal samples.
As can be seen, drug release was substantially faster from the investigated capsules in the presence
of fecal samples. Such a finding clearly validates the intended approach of enzyme-triggered drug
release allowing for colon targeting. This was true for both grades of HPMC 4M and 15LV. The
acetaminophen release was faster from AMY/HPMC 15LV based capsules compared to AMY/HPMC
4M based ones in the presence and absence of fecal samples. This can again be attributed to the
difference in polymer molecular weight, as discussed above. Please note that the lag times for drug
release were prolonged compared to the results observed using the modified disintegration apparatus
(Figure 5), also in the absence of fecal bacteria. This can be attributed to the different mechanical stresses
encountered in the two experimental setups during drug release (the difference between phosphate
buffer pH 6.8 and the culture medium probably only plays a minor role).
3. Materials and Methods
3.1. Materials
Swellable/soluble hydrophilic polymers: HPMC (AffiniSol™ 15LV and 4M grades; Dow Chemical,
Pittsburg, CA, USA; HPMC 15LV and HPMC 4M, respectively); HPC (Klucel® LF, Ashland, Chatham,
NJ, USA); PVA (Gohsenol™ EG 05P and EG 40P, Nippon Gohsei, Tokyo, J; PVA 05 and PVA 40,
respectively).
Polysaccharides sensitive to bacterial degradation: high-amylose maize starch (Amylo® N-460,
Roquette Pharma, Souvigné, France; AMY); hydroxypropyl modified pea starch, (Lycoat® RS780,
Roquette harma, Souvigné, France; LYC).
Plasticizers: PEG 1500 (Clariant Masterbatches, Milan, Italy); GLY (Pharmagel, Milan, Italy).
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Tracers: blue dye-containing preparation (Kollicoat® IR Brilliant Blue, BASF, Ludwigshafen, D,
Germany); acetaminophen (Rhodia, Milan, Italy).
3.2. Methods
3.2.1. Preparation of Polymeric Formulations
Formulations based on a single polymer:
The polymer (AMY, LYC, HPC, HMPCs or PVAs) was kept in an oven at 40 ◦C for 24 h prior to
placing it into a mortar. The plasticizer was manually added under continuous mixing with a pestle.
The amount of plasticizer is expressed as percentage “weight by weight”, based on the dry polymer
(=100%).
Formulations based on polymeric blends:
First, the single polymers were plasticized as described above: one swellable/soluble hydrophilic
polymer and one polysaccharide sensitive to bacterial degradation. Then, the two plasticized polymers
were manually mixed in a mortar in a 1:1 weight: weight ratio.
3.2.2. HME
HME was performed using a twin-screw extruder (HAAKE™ MiniLab II, Thermo Scientific™,
Bannockburn, IL, USA), equipped with two conical counter-rotating screws (diameter 5/14 mm, length
109.5 mm). Polymeric formulations were manually loaded into the barrel and extruded through a
rectangular die (dimensions: 1 × 3 mm). The HME process parameters were set up and are reported in
Section 2.1.
3.2.3. IM
IM was performed using a bench-top micromolding machine (BabyPlast 6/10P; Cronoplast S.L., E;
Rambaldi S.r.l., Lecco, Italy), equipped with: i) a disk-shaped mold (ø = 30 mm), with a central gate,
allowing the variance of cavity thickness (nominal 200 and 600 µm) or ii) a mold with a hot-runner
and two interchangeable inserts for the manufacturing of matching capsule caps and capsule bodies
(600 µm nominal shell thickness). The polymeric formulations described in Section 3.2.1 were manually
loaded into the plasticating unit of BabyPlast and fed into the injection chamber by a loading plunger.
Two different and consecutive injection pressures (P1–P2), maintained for a selected time (t1–t2), were
applied by a piston moving at two distinct rates (v1–v2; v is expressed as percentage of the maximum
rate), in order to inject the polymeric melt into the mold cavity. For injection pressures and injection
rates, minimum values were chosen and progressively increased until satisfactory products were
obtained. In the case of AMY, disks were fabricated not only from the polymeric formulation described
in Section 3.2.1, but also from pellets, which were manually cut from extrudates of the same composition
and prepared as described in Section 3.2.2. The process parameters selected for the fabrication of disks
and capsule shells are reported in Section 2.3.
3.2.4. WC and RDM
Injection molded disks were characterized in terms of water uptake and mass loss upon exposure
to different aqueous media, as described in the following.
Then, 600 µm thick disks (n = 9) were weighed (analytical balance BP211, Sartorius, Göttingen, D,
Germany) to record the initial mass, and then immersed in 125 mL phosphate buffer pH = 6.8 (USP 42),
and kept at 37 ± 0.5 ◦C under magnetic stirring (125 rpm). For the easy manual recovery of samples at
the end of the test and prevention of damages, a customized metal support was used;
Accordingly, 200 µm and 600 µm thick disks (n = 9) were weighed (analytical balance BP211,
Sartorius, Göttingen, D, Germany) to record the initial mass and then immersed in 100 mL of fluid
after insertion into a 180 µm tubular mesh, closed with clips at both ends to facilitate manual recovery
at the end of the test. The fluid was either free culture medium or culture medium inoculated with
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fecal samples of patients suffering from ulcerative colitis. Culture medium was prepared by dissolving
5 g tryptone, 3 g yeast extract, 2.5 g NaCl, 1.5 g beef extract and 0.3 g l-cysteine hydrochloride hydrate
in 1 L of distilled water (pH = 7.0 ± 0.2) and subsequent sterilization in an autoclave (20 min at 115 ◦C).
Fecal samples were diluted about 1:200 (final concentration = 0.0125% w/v) with cysteinated ringer
solution, in order to have an initial concentration of about 7 log CFU/mL with only minor variation
due to inherent individual differences. Furthermore, 2.5 mL of the fecal suspension was diluted with
culture medium up to 100 mL. The systems were kept at 37 ± 0.5 ◦C under horizontal shaking (80 rpm;
Stuart SSM1 Mini Orbital Shaker, VWR, Monroeville, PA, USA) and anaerobic conditions, as previously
described in detail [49,50].
At pre-determined time points, samples were withdrawn, manually blotted to remove the excess
of fluid, and weighed. The disks were then dried at 60 ◦C until constant weight. WC and RDM were
calculated according to the following equations:
WC (%) =
[
(Wm −Wd)
Wm
]
× 100 (1)
where Wm is the mass of the wet sample upon withdrawal at the sampling time point, and Wd is the
mass of the respective sample after drying to constant weight;
RDM(%) =
(
1−
[
(Wi −Wd)
Wi
])
× 100 (2)
where Wi is the initial dry mass of the sample.
3.2.5. Barrier Performance of Molded Disks
Molded disks (n = 6) were tested for barrier performance by using them to close the donor
compartment of manually assembled cells, modified from the extraction cells used for the dissolution
test of transdermal patches [33]. The donor compartment was filled with about 20 mg of Kollicoat®
IR brilliant blue as a tracer. The manually assembled cells were placed at the bottom of vessels of a
USP 42 dissolution apparatus II (500 mL phosphate buffer pH 6.8 as the acceptor medium, 37 ± 0.5 ◦C,
100 rpm paddle rotating speed; Dissolution System 2100B, Distek, North Brunswick Township, NJ,
USA). Barrier resistance was visually evaluated and quantified as the time to the appearance of a first
tear on the disk (i.e., rupture time), highlighted by the coloring of the acceptor medium.
3.2.6. In Vitro Release from Capsules
Capsule bodies (n= 6) were manually filled with approximately 50 mg (coefficient of variation < 2)
acetaminophen and then closed with matching caps. Each assembled capsule was then inserted into a
sinker. Drug release was measured as follows:
Using a modified three-position disintegration apparatus (Sotax, Lugano, CH): a single capsule
was positioned in one of the 6 available tubes of each basket-rack assembly, that moved at 31 cycles/min
in a vessel filled with 800 mL phosphate buffer pH 6.8, kept at 37 ± 0.5 ◦C. Fluid samples were
automatically withdrawn at predetermined time points and assayed spectrophotometrically (λ =
248 nm; Lambda25, Perkin Elmer, UK).
Capsules were placed in closed flasks containing 100 mL culture medium (free of fecal samples),
or 100 mL culture medium inoculated with fecal samples (1% w/v) from patients suffering from
inflammatory bowel diseases (i.e., ulcerative colitis and Crohn’s disease) under anaerobic conditions.
At predetermined time points, 2 mL fluid samples were withdrawn, centrifuged (13,000 rpm, 5 min)
and filtered (0.22 µm), before being analyzed by HPLC (Thermo Fisher Scientific Ultimate 3000 Series,
Boston, MA, USA). A Gemini® 5 µm C18 110 Å, 150 × 4.6 mm column (Phenomenex, London, UK)
was used. The mobile phase was a blend of: A) water adjusted to pH 2 with orthophosphoric acid,
and B) acetonitrile. A linear gradient program was run as follows: 0–10 min: 5–20% B; 10–11 min,
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20–5% B. The flow rate was 1 mL/min, and 10 µL samples were injected. Acetaminophen was detected
spectrophotometrically (λ = 248 nm).
4. Conclusions
In the present work, the suitability of IM for the preparation of empty capsule shells as a
platform for colon targeting was demonstrated, combining time-dependent and enzyme-triggered
approaches. The composition of the systems (i.e., type and amount of plasticizer, types of polymers) and
processing conditions were selected. By combining polymeric formulations based on AMY and HPMCs
with different molecular weight, the possibility of modulating independent and complementary
time-dependent and enzymatic-degradation mechanisms was demonstrated. This should allow
circumventing issues related to single-trigger systems and improve the site selectivity of drug release.
Furthermore, the selection of the swellable/soluble hydrophilic polymer might result in different release
patterns and in vivo performance of the capsules, once the system has reached the colon. For example,
the presence of a highly viscous gel characterized by a relatively slow dissolution/erosion rate, might
either prevent or defer the exposure of AMY to the colonic fluids and therefore limit or slow down its
degradation by the bacterial enzymes. Considering that the type and ratio of the two components
in the blend can be adjusted, further possibilities of modulating the degradation behavior are likely,
representing an advantageous aspect for the development of a novel colon delivery platform.
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Abbreviations
AMY Amylo® N-460
CFU Colony-forming unit
3D Three-dimensional
DDSs Drug delivery systems
GLY Glycerol
HME Hot melt extrusion
HPC Hydroxypropyl cellulose
HPMC Hydroxypropyl methylcellulose
HPLC High pressure liquid chromatography
IM Injection molding
LYC Lycoat® RS780
PEG Polyethylene glycol
PVA Poly(vinyl alcohol)
RDM Residual dry mass
USP United States Pharmacopeia
WC Water content
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